Top waste, fraud, and abuse red flags, and how to identify them

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-waste-fraud-and-abuse-red-flags-and-how-identify-them?GUID=A13E56ED-9529-4BD1-98E9-318F5373C18F&rememberme=1&ts=17112017

Image result for red flags

 

In some cases of healthcare fraud, it’s easy to spot red flags. But in large healthcare organizations, or on the payer end, fraud and waste can be more difficult to detect through layers and layers of data.

During his presentation, “Using Analytics to Drive Payment Integrity and Reduce Fraud,” on November 16 at the annual National Health Care Anti-Fraud Association Annual Conference in Orlando, Ben Wright, AHFI, senior payment integrity solutions architect at SAS Fraud & Security Intelligence Global Practice, discussed how health systems and payers can  meet these challenges.

 “In larger healthcare organization, you want to make sure you are protecting from larger loss,” Wright said. “Waste and abuse are clearly much more expensive in most cases than intentional fraud.”

Managed care has not reduced fraud, waste, and abuse in the way it was hoped at inception, Wright he said, and the need to coordinate efforts and create enterprise-wide solutions has never been greater.

How technology can help

Analytics platforms can help identify subtle changes in behavior and practice that can be indicative of fraud, waste or abuse, Wright said. This can include identifying errors and duplicates in the billing system, and fraud and wasteful or abusive practices.

He noted three types of analytics that can help:

1.              Behavior analytics is the closest approximation of true fraud detection, he said. It can help systems identify behaviors that are most likely to indicate fraud. For example, a provider who prescribes outside of the norm for their specialty, or a practice that documents more patient encounters than makes sense.

2.              Claim analytics uses customized product or policy data to sift through abuses of rule sets, coding designations, prescription rates, and more.

3.              Clinical targeting reviews level of care issues.

They key to using these analytics, Wright said, is to view them as enterprise-wide and to coordinate efforts across platforms and services, not within silos.

A hybrid of the above analytics methods is most effective, he said, using behavioral analytics, payment policy and coding guidelines, and clinical targeting together.

Examples of big red flags

Wright shared with Managed Healthcare Executive several examples of service line issues or red flags to watch out for.

·      Provider specialty mismatch. A provider who has general medical training but a specialty in neurology might warrant closer investigation if he is prescribing outside his specialty’s norm. Say a neurologist is prescribing a lot of opioid medications, Wright said. Investigators may want to review what tests are being ordered and why. It may become clear that the tests ordered and the level of evaluation of the patients for which those medications were ordered does not match what you might expect from a neurologist. “If you find that the tests don’t match, that would be a behavior that would be atypical for a community of neurologists,” Wright said. “That provider might get additional scrutiny. It’s a combination of their behavior versus behavior that might be expected.”

·      Locum tenens physician rates. These physicians fill in for absent physicians, but sometimes can be used to increase patient volume and revenue. In one case, Wright said, a physician was seeing patients in an emergency department while a locum tenens provider saw the physician’s other patients in the office. All of patient visits were paid at the provider’s rate, but the locum tenens should have been paid at a lower rate. This is a violation of locum tenens rules, but also indicates oan inappropriate agreement between the provider and the hospital, as well as an exploitation of the locum tenens physician.

There is so much data at a plan or health system’s fingertips now, the key is managing it to get the information you need. Increased specificity of coding, for example, provides a lot of data on disease management, but not a lot toward improving payment integrity.

 “Intentional fraud is a very small percentage of the community, but it’ a huge amount of dollars,” Wright said. “Meanwhile, waste and abuse can happen on many levels.”

Liquid Gold: Pain Doctors Soak Up Profits By Screening Urine For Drugs

https://khn.org/news/liquid-gold-pain-doctors-soak-up-profits-by-screening-urine-for-drugs/

The cups of urine travel by express mail to the Comprehensive Pain Specialists lab in an industrial park in Brentwood, Tenn., not far from Nashville. Most days bring more than 700 of the little sealed cups from clinics across 10 states, wrapped in red-tagged waste bags. The network treats about 48,000 people each month, and many will be tested for drugs.

Gloved lab techs keep busy inside the cavernous facility, piping smaller urine samples into tubes. First there are tests to detect opiates that patients have been prescribed by CPS doctors. A second set identifies a wide range of drugs, both legal and illegal, in the urine. The doctors’ orders are displayed on computer screens and tracked by electronic medical records. Test results go back to the clinics in four to five days. The urine ends up stored for a month inside a massive walk-in refrigerator.

The high-tech testing lab’s raw material has become liquid gold for the doctors who own Comprehensive Pain Specialists. This testing process, driven by the nation’s epidemic of painkiller addiction, generates profits across the doctor-owned network of 54 clinics, the largest pain-treatment practice in the Southeast. Medicare paid the company at least $11 million for urine and related tests in 2014, when five of its professionals stood among the nation’s top billers. One nurse practitioner at the company’s clinic in Cleveland, Tenn., single-handedly generated $1.1 million in Medicare billings for urine tests that year, according to Medicare records.

Dr. Peter Kroll, one of the founders of CPS and its medical director, billed Medicare $1.8 million for these drug tests in 2015. He said the costly tests are medically justified to monitor patients on pain pills against risks of addiction or even selling of pills on the black market. “I have to know the medicine is safe and you’re taking it,” Kroll, 46, said in an interview. Kroll said that several states in which CPS is active have high rates of opioid use, which requires more urine testing.

Kaiser Health News, with assistance from researchers at the Mayo Clinic, analyzed available billing data from Medicare and private insurance billing nationwide, and found that spending on urine screens and related genetic tests quadrupled from 2011 to 2014 to an estimated $8.5 billion a year — more than the entire budget of the Environmental Protection Agency. The federal government paid providers more to conduct urine drug tests in 2014 than it spent on the four most recommended cancer screenings combined.

Yet there are virtually no national standards regarding who gets tested, for which drugs and how often. Medicare has spent tens of millions of dollars on tests to detect drugs that presented minimal abuse danger for most patients, according to arguments made by government lawyers in court cases that challenge the standing orders to test patients for drugs. Payments have surged for urine tests for street drugs such as cocaine, PCP and ecstasy, which seldom have been detected in tests done on pain patients. In fact, court records show some of those tests showed up positive just 1 percent of the time.

Urine testing has become particularly lucrative for doctors who operate their own labs. In 2014 and 2015, Medicare paid $1 million or more for drug-related tests billed by health professionals at more than 50 pain management practices across the U.S. At a dozen practices, Medicare billings were twice that high.

Thirty-one pain practitioners received 80 percent or more of their Medicare income just from urine testing, which a federal official called a “red flag” that may signal overuse and could lead to a federal investigation.

“We’re focused on the fact that many physicians are making more money on testing than treating patients,” said Jason Mehta, an assistant U.S. attorney in Jacksonville, Fla. “It is troubling to see providers test everyone for every class of drugs every time they come in.”